Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomi… Read more
Dr. Lal Path Labs Ltd. - Asset Resilience Ratio
Dr. Lal Path Labs Ltd. (LALPATHLAB) has an Asset Resilience Ratio of 43.99% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Dr. Lal Path Labs Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Dr. Lal Path Labs Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹8.16 Billion | 27.58% |
| Short-term Investments | ₹4.86 Billion | 16.41% |
| Total Liquid Assets | ₹13.02 Billion | 43.99% |
Asset Resilience Insights
- Very High Liquidity: Dr. Lal Path Labs Ltd. maintains exceptional liquid asset reserves at 43.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Dr. Lal Path Labs Ltd. Industry Peers by Asset Resilience Ratio
Compare Dr. Lal Path Labs Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Dr. Lal Path Labs Ltd. (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Dr. Lal Path Labs Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 41.96% | ₹11.40 Billion | ₹27.17 Billion | +4.60pp |
| 2024-03-31 | 37.37% | ₹9.18 Billion | ₹24.56 Billion | +2.26pp |
| 2023-03-31 | 35.11% | ₹8.38 Billion | ₹23.86 Billion | +7.03pp |
| 2022-03-31 | 28.08% | ₹6.61 Billion | ₹23.53 Billion | -29.58pp |
| 2021-03-31 | 57.66% | ₹9.58 Billion | ₹16.61 Billion | +5.29pp |
| 2020-03-31 | 52.37% | ₹7.20 Billion | ₹13.74 Billion | -7.23pp |
| 2019-03-31 | 59.60% | ₹6.50 Billion | ₹10.90 Billion | +7.26pp |
| 2018-03-31 | 52.34% | ₹4.81 Billion | ₹9.19 Billion | +7.70pp |
| 2017-03-31 | 44.65% | ₹3.41 Billion | ₹7.64 Billion | +0.62pp |
| 2016-03-31 | 44.03% | ₹2.75 Billion | ₹6.25 Billion | +9.77pp |
| 2015-03-31 | 34.26% | ₹1.63 Billion | ₹4.75 Billion | +6.24pp |
| 2014-03-31 | 28.02% | ₹984.88 Million | ₹3.52 Billion | +6.11pp |
| 2013-03-31 | 21.91% | ₹589.39 Million | ₹2.69 Billion | +16.13pp |
| 2012-03-31 | 5.78% | ₹102.37 Million | ₹1.77 Billion | -5.43pp |
| 2011-03-31 | 11.21% | ₹190.20 Million | ₹1.70 Billion | -- |